|
Jul 28
|
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
|
|
Jul 24
|
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
|
|
Jul 3
|
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing
|
|
Jul 1
|
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
|
|
Jul 1
|
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
|
|
May 9
|
Apellis Pharmaceuticals' Funding Gaps, Weak Syfovre Sales Cloud Outlook, BofA Says
|
|
May 9
|
Apellis price target lowered to $20 from $28 at Scotiabank
|
|
May 9
|
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’
|
|
May 9
|
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back?
|
|
May 8
|
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
|
|
May 8
|
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ...
|
|
May 8
|
Q1 2025 Apellis Pharmaceuticals Inc Earnings Call
|
|
May 7
|
Why Apellis Pharmaceuticals Wilted on Wednesday
|
|
May 7
|
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 7
|
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 7
|
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
|
|
May 6
|
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
Feb 23
|
Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 21
|
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 21
|
High Growth Tech Stocks In The United States To Watch
|